Top

Current Cardiology Reports

Published in:

Open Access 01-09-2019 | Magnetic Resonance Imaging | Cardiac PET, CT, and MRI (P Schoenhagen, Section Editor)

Cardiac Amyloidosis: Updates in Imaging

Authors: Liza Chacko, Raffaele Martone, Francesco Cappelli, Marianna Fontana

Published in: Current Cardiology Reports | Issue 9/2019

Abstract

Purpose of Review

We summarize key features pertaining to the two most commonly encountered types of cardiac amyloidosis (CA), monoclonal immunoglobulin light chain (AL) and transthyretin type (ATTR), expanding upon the clinical application and utility of various imaging techniques in diagnosing CA.

Recent Findings

Advances in imaging have led to earlier identification, improved diagnosis of CA and higher discriminatory power to differentiate CA from other hypertrophic phenocopies. The application of cardiac magnetic resonance imaging (CMR) has led to a deeper understanding of underlying pathophysiological processes in CA, owing largely to its intrinsic tissue characterization properties. The widespread adoption of bone scintigraphy algorithms has reduced the need for cardiac biopsy and improved diagnostic confidence in ATTR CA.

Summary

As new treatments for CA are rapidly developing, there will be even greater reliance on imaging, as the requirement to diagnose disease earlier, monitor response and amend treatment strategies accordingly intensifies.

Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6:214–20. https://doi.org/10.1016/j.coph.2005.10.005.CrossRefPubMed

Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–54. https://doi.org/10.1016/S0140-6736(15)01274-X.CrossRefPubMed

Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018;18:s30–s5. https://doi.org/10.7861/clinmedicine.18-2-s30. CrossRef

Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, et al. Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology. 2015;277:388–97. https://doi.org/10.1148/radiol.2015141744.CrossRefPubMed

Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68:1323–41. https://doi.org/10.1016/j.jacc.2016.06.053.CrossRefPubMed

Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. J Am Coll Cardiol. 2015;66:2451–66. https://doi.org/10.1016/j.jacc.2015.09.075.CrossRefPubMed

Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817–22.PubMed

Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525–32. https://doi.org/10.1111/bjh.12286.CrossRefPubMedPubMedCentral

Aimo A, Buda G, Fontana M, Barison A, Vergaro G, Emdin M, et al. Therapies for cardiac light chain amyloidosis: An update. Int J Cardiol. 2018;271:152–60. https://doi.org/10.1016/j.ijcard.2018.05.018.CrossRefPubMed

10.

Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103:1065–72. https://doi.org/10.1136/heartjnl-2016-310704. CrossRefPubMedPubMedCentral

11.

Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23:209–13. https://doi.org/10.1080/13506129.2016.1257986.CrossRefPubMed

12.

Castaño AND, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87.CrossRef

13.

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G. de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–94. https://doi.org/10.1093/eurheartj/ehv338. CrossRefPubMed

14.

Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2:e000098. https://doi.org/10.1161/JAHA.113.000098.CrossRefPubMedPubMedCentral

15.

Carr AS, Pelayo-Negro AL, Evans MR, Laura M, Blake J, Stancanelli C, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry. 2016;87:620–7. https://doi.org/10.1136/jnnp-2015-310907.CrossRefPubMed

16.

Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015;28:201–7. https://doi.org/10.1038/modpathol.2014.102.CrossRefPubMed

17.

Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017;318:962–3. https://doi.org/10.1001/jama.2017.9236. CrossRefPubMedPubMedCentral

18.

Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63–76. https://doi.org/10.1185/03007995.2012.754348.CrossRefPubMed

19.

Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35:E2403–12. https://doi.org/10.1002/humu.22619.CrossRefPubMed

20.

Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22:171–4. https://doi.org/10.3109/13506129.2015.1051219.CrossRefPubMed

21.

Castano A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20:163–78. https://doi.org/10.1007/s10741-014-9462-7.CrossRefPubMedPubMedCentral

22.

Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017;70:466–77. https://doi.org/10.1016/j.jacc.2017.05.053.CrossRefPubMed

23.

• Gonzalez-Lopez E, Gagliardi C, Dominguez F, Quarta CC, de Haro-Del Moral FJ, Milandri A, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38:1895–904. https://doi.org/10.1093/eurheartj/ehx043 This study provides a detailed characterisation of cardiac ATTR wild-type amyloidosis emphasising the heterogenous nature of the disease, prompting clinicians to be aware of the broad clinical spectrum of ATTRwt. CrossRefPubMed

24.

Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28:10–21. https://doi.org/10.1016/j.tcm.2017.07.004.CrossRefPubMed

25.

Murphy L, Falk RH. Left atrial kinetic energy in AL amyloidosis: can it detect early dysfunction? Am J Cardiol. 2000;86:244–6.CrossRef

26.

Modesto KM, Dispenzieri A, Cauduro SA, Lacy M, Khandheria BK, Pellikka PA, et al. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J. 2005;26:173–9. https://doi.org/10.1093/eurheartj/ehi040.CrossRefPubMed

27.

Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116:2420–6. https://doi.org/10.1161/CIRCULATIONAHA.107.697763.CrossRefPubMed

28.

Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, et al. High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. J Am Coll Cardiol. 2019;73:1733–4. https://doi.org/10.1016/j.jacc.2019.01.035.CrossRefPubMed

29.

Siepen FAD, Bauer R, Voss A, Hein S, Aurich M, Riffel J, et al. Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin Res Cardiol. 2018;107:158–69. https://doi.org/10.1007/s00392-017-1167-1.CrossRefPubMed

30.

Riffel JH, Mereles D, Emami M, Korosoglou G, Kristen AV, Aurich M, et al. Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis. Amyloid. 2015;22:45–53. https://doi.org/10.3109/13506129.2014.992515.CrossRefPubMed

31.

Rapezzi C, Fontana M. Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis: Is it Just Amyloid Infiltration? JACC Cardiovasc Imaging. 2019:12:1174–6. https://doi.org/10.1016/j.jcmg.2018.07.007.PubMed

32.

Senapati A, Sperry BW, Grodin JL, Kusunose K, Thavendiranathan P, Jaber W, et al. Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart. 2016;102:748–54. https://doi.org/10.1136/heartjnl-2015-308657.CrossRefPubMed

33.

Falk RH, Quarta CC. Echocardiography in cardiac amyloidosis. Heart Fail Rev. 2015;20:125–31. https://doi.org/10.1007/s10741-014-9466-3.CrossRefPubMed

34.

Porciani MC, Lilli A, Perfetto F, Cappelli F, Massimiliano Rao C, Del Pace S, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid. 2009;16:63–70. https://doi.org/10.1080/13506120902879681.CrossRefPubMed

35.

Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186–93. https://doi.org/10.1161/01.CIR.0000152819.97857.9D.CrossRefPubMed

36.

Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132:1570–9. https://doi.org/10.1161/CIRCULATIONAHA.115.016567.CrossRefPubMedPubMedCentral

37.

Radiology ACo. ACR Manual On Contrast Media. 2018 Available from: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf.

38.

McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, et al. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology. 2018;289:517–34. https://doi.org/10.1148/radiol.2018181151.CrossRefPubMed

39.

McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology. 2015;275:772–82. https://doi.org/10.1148/radiol.15150025.CrossRefPubMed

40.

Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, et al. Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. Radiology. 2015;276:228–32. https://doi.org/10.1148/radiol.2015142690.CrossRefPubMed

41.

Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol. 2016;26:807–15. https://doi.org/10.1007/s00330-015-3879-9.CrossRefPubMed

42.

Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, et al. Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function. Investig Radiol. 2016;51:447–53. https://doi.org/10.1097/RLI.0000000000000252.CrossRef

43.

Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6:488–97. https://doi.org/10.1016/j.jcmg.2012.11.013.CrossRefPubMed

44.

Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:157–65. https://doi.org/10.1016/j.jcmg.2013.10.008.CrossRefPubMed

45.

Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34–9. https://doi.org/10.1161/CIRCIMAGING.112.978627.CrossRefPubMed

46.

Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S, et al. CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. JACC Cardiovasc Imaging. 2018;11:152–4. https://doi.org/10.1016/j.jcmg.2017.02.012.CrossRefPubMed

47.

Ferreira VM, Piechnik SK, Robson MD, Neubauer S, Karamitsos TD. Myocardial tissue characterization by magnetic resonance imaging: novel applications of T1 and T2 mapping. J Thorac Imaging. 2014;29:147–54. https://doi.org/10.1097/RTI.0000000000000077.CrossRefPubMedPubMedCentral

48.

• Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, et al. Myocardial Edema and Prognosis in Amyloidosis. J Am Coll Cardiol. 2018;71:2919–31. https://doi.org/10.1016/j.jacc.2018.03.536 Findings from this study suggested myocardial oedema as a mechanism of damage in addition to amyoid infiltration contributing to mortality in amyloidosis. CrossRefPubMed

49.

Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–84. https://doi.org/10.1016/j.jacc.2005.05.073.CrossRefPubMed

50.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133:2404–12. https://doi.org/10.1161/CIRCULATIONAHA.116.021612.CrossRefPubMed

51.

Falk RH, Lee VW, Rubinow A, Hood WB, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983;51:826–30.CrossRef

52.

Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15:1289–98. https://doi.org/10.1093/ehjci/jeu107.CrossRefPubMed

53.

Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18:1344–50. https://doi.org/10.1093/ehjci/jew325.CrossRefPubMed

54.

Cappelli F, Gallini C, Costanzo EN, Tutino F, Ciaccio A, Vaggelli L, et al. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon. Int J Cardiol. 2018;254:346–50. https://doi.org/10.1016/j.ijcard.2017.10.027.CrossRefPubMed

55.

Sperry BW, Gonzalez MH, Brunken R, Cerqueira MD, Hanna M, Jaber WA. Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis. J Nucl Cardiol. 2018. https://doi.org/10.1007/s12350-017-1166-7.

56.

Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:1652–62. https://doi.org/10.1007/s00259-014-2787-6.CrossRefPubMed

57.

Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213–20. https://doi.org/10.2967/jnumed.111.102053.CrossRefPubMed

58.

Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2015;8:50–9.CrossRef

59.

Osborne DR, Acuff SN, Stuckey A, Wall JS. A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir. Front Cardiovasc Med. 2015;2:23. https://doi.org/10.3389/fcvm.2015.00023.CrossRefPubMedPubMedCentral

60.

Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study. J Nucl Med. 2016;57:1733–9. https://doi.org/10.2967/jnumed.115.169870.CrossRefPubMed

61.

Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51:1022–30. https://doi.org/10.1016/j.jacc.2007.10.049.CrossRefPubMed

62.

Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751–7. https://doi.org/10.1200/JCO.2004.03.029.CrossRefPubMed

63.

Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799–806. https://doi.org/10.1093/eurheartj/ehx589.CrossRefPubMed

64.

Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016;68:1014–20. https://doi.org/10.1016/j.jacc.2016.06.033.CrossRefPubMed

65.

Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, et al. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. JACC Cardiovasc Imaging. 2019:12:823–33. https://doi.org/10.1016/j.jcmg.2018.02.016.PubMed

66.

Binder C, Duca F, Stelzer PD, Nitsche C, Rettl R, Aschauer S, et al. Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. Eur Heart J Cardiovasc Imaging. 2019:20:512–24. https://doi.org/10.1093/ehjci/jey225.CrossRef

67.

Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36:244–51. https://doi.org/10.1093/eurheartj/ehu444.CrossRefPubMed

68.

Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J. 2018;8:44. https://doi.org/10.1038/s41408-018-0080-9.CrossRefPubMedPubMedCentral

69.

• Merlini G, Dispenzieri A, Sanchorawala V, Schonland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:1–19. https://doi.org/10.1038/s41572-018-0034-3. This review provides a detailed overview of the clinical presentation, disease mechanisms and treatment strategies in AL amyloidosis.

70.

Ruberg FL. Cardiac Amyloidosis: A Zebra Hiding in Plain Sight? Circ Cardiovasc Imaging. 2017;10:e006186. https://doi.org/10.1161/CIRCIMAGING.117.006186.CrossRefPubMed

71.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379:22–31. https://doi.org/10.1056/NEJMoa1716793.CrossRefPubMed

72.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007–16. https://doi.org/10.1056/NEJMoa1805689.CrossRefPubMed

73.

Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379:11–21. https://doi.org/10.1056/NEJMoa1716153.CrossRefPubMed

Title: Cardiac Amyloidosis: Updates in Imaging
Authors: Liza Chacko
Raffaele Martone
Francesco Cappelli
Marianna Fontana
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Echocardiography
Cardiomyopathy
Cardiac Amyloidosis
Echocardiography
Scintigraphy
Amyloidosis
Published in: Current Cardiology Reports / Issue 9/2019
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-019-1180-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cardiac Amyloidosis: Updates in Imaging

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 9/2019

The Assessment of Cardiac Masses by Cardiac CT and CMR Including Pre-op 3D Reconstruction and Planning

Imaging Approaches for Coronary Artery Anomalies: Purpose and Techniques

Do Thiazide Diuretics Increase the Risk of Skin Cancer? A Critical Review of the Scientific Evidence and Updated Meta-Analysis

Echocardiographic Diastolic Stress Testing: What Does It Add?

Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment

For Whom the Bell Tolls

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page